BTN1A1, a element of the butyrophilin group , represents an fascinating therapeutic target for multiple immune disorders. The ICT-01-N297A immunoglobin , specifically designed to bind BTN1A1, offers a novel https://www.targetmol.com/compound/ict_01_n297a